SIREN : 414431999
NOVOTEC is a French company founded 28 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in BRON (69500), this company of category PME shows in 2024 a revenue of 460 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 460 499 € | 416 119 € | 471 891 € | 530 516 € | 243 523 € | 445 961 € | 459 687 € | 310 606 € |
| Net income | 47 446 € | 22 940 € | 20 121 € | 23 219 € | -100 042 € | 15 479 € | 37 278 € | 31 194 € |
| EBITDA | 13 661 € | 40 864 € | 31 827 € | 36 024 € | -87 115 € | 15 016 € | 15 796 € | 4 616 € |
| Net margin | 10.3% | 5.5% | 4.3% | 4.4% | -41.1% | 3.5% | 8.1% | 10.0% |
In 2024, NOVOTEC achieves revenue of 460 k€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.0%. Vs 2023, growth of +11% (416 k€ -> 460 k€). After deducting consumption (72 k€), gross margin stands at 389 k€, i.e. a rate of 84%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 14 k€, representing 3.0% of revenue. Warning negative scissor effect: despite revenue change (+11%), EBITDA varies by -67%, reducing margin by 6.9 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 47 k€, i.e. 10.3% of revenue. This profit can be retained or distributed to shareholders.
460 499 €
388 708 €
13 661 €
1 182 €
47 446 €
3.0%
The debt ratio (= Financial debt / Equity x 100) stands at 23%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 68%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 13.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
23.207%
68.001%
13.013%
1.709
16.9%
In 2024, the debt ratio of NOVOTEC (23.21) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of NOVOTEC (68.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of NOVOTEC (1.71) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 553.71. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.5x. Operating income very largely covers interest expenses: high safety margin.
553.711
6.471
In 2024, the liquidity ratio of NOVOTEC (553.71) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of NOVOTEC (6.5x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 74 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 82 days. Favorable situation: supplier credit is longer than customer credit by 8 days. Inventory turnover is 353 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 396 days of revenue, i.e. 507 k€ to permanently finance. Over 2016-2024, WCR increased by +25%, requiring additional financing.
506 503 €
74 j
82 j
353 j
396 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 9 466€ to 29 095€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NOVOTEC with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of NOVOTEC in 2024 is 460 k€.
Yes, NOVOTEC generated a net profit of 47 k€ in 2024.
The headquarters of NOVOTEC is located in BRON (69500), in the department Rhone.
The tax return of NOVOTEC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NOVOTEC operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.